NSE / BSEHealthcare
β‚Ή1533.95-28.30-1.81%
P/E65.0Mkt Capβ‚Ή11.14 K CrEV/EBITDA115.2

RUBICON RESEARCH LIMITED

P/E65.0Mkt Capβ‚Ή11.14 K CrEV/EBITDA115.2
Company Profile

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
β€”
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 144.47% over 1Y
Monthly Returns

Historically, Jun has averaged the highest return (+47.3%); May the lowest (-2.0%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+0.8%Neutral MonthJan 2026: +0.79%+14.3%Positive MonthFeb 2026: +14.33%-1.1%Neutral MonthMar 2026: -1.09%+25.6%Positive MonthApr 2026: +25.61%-2.0%Neutral MonthMay 2026: -1.97%+47.3%Positive MonthJun 2026: +47.33%+9.5%*Positive MonthJul 2026: +9.45%β€”β€”β€”β€”β€”
2025β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”+6.1%Positive MonthNov 2025: +6.06%+3.3%Positive MonthDec 2025: +3.34%
AvgΒ±SD+0.8%Β±0.0%+14.3%Β±0.0%-1.1%Β±0.0%+25.6%Β±0.0%-2.0%Β±0.0%+47.3%Β±0.0%+9.5%Β±0.0%β€”β€”β€”+6.1%Β±0.0%+3.3%Β±0.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 2 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 2.263x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.07 K Crβ–² 70.2%
EBITDA Growthβ€”
Net Profitβ‚Ή168.00 Crβ–² 600.0%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 1400.0%
Revenue CAGR 5Y19.1%
EBITDA CAGR 5Y-1.7%
Net Profit CAGR 5Y-16.5%
NP Growth 1Y600.0%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.07 K Crβ€”β‚Ή168.00 Crβ€”β€”25.2%70.2%600.0%
Mar 2024β‚Ή631.00 Crβ€”β‚Ή24.00 Crβ€”β€”5.0%60.2%-241.2%
Mar 2023β‚Ή394.00 Crβ€”β‚Ή-17.00β€”β€”-5.9%-1.5%-200.0%
Mar 2022β‚Ή400.00 Crβ€”β‚Ή17.00 Crβ€”β€”4.0%20.8%-67.9%
Mar 2021β‚Ή331.00 Crβ€”β‚Ή53.00 Crβ€”β€”12.9%25.9%-10.2%
Mar 2020β‚Ή263.00 Crβ€”β‚Ή59.00 Crβ€”β€”16.6%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue / Net Sales2633314003946311,074
Total Expenses173220360375557803
EBIT / Operating Profit90111401873271
OPM %34%34%10%5%12%25%
Other Income181117252619
Finance Costs699193134
Depreciation & Amortisation182832363532
Profit Before Tax848517-1134223
Tax %29%38%1%53%29%25%
Net Profit / PAT595317-1724168
EPS (β‚Ή)116.53104.4632.90-33.311.6010.87
Dividend Payout %2%0%0%-2%1%0%

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
RUBICON RESEARCH LIMITEDthis co.β‚Ή11.14 K Crβ‚Ή1.07 K Cr65.000.00115.2070.2%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of RUBICON RESEARCH LIMITED and the metrics that matter.

Browse the full Equiscale Academy